Skip to content
UpLiftRx
MedicationsLabsProvidersVisitsOrdersDashboardSign in
UpLiftRx
MedicationsLabsProvidersVisitsOrdersDashboard
Sign in
Transparency
  • Company
  • Our clinicians
  • Pharmacy partners
  • Where we operate
  • Accreditation
Legal
  • Terms of Service
  • Privacy Policy
  • Notice of Privacy Practices
  • Telehealth Consent
  • Auto-Renewal Terms
  • Refund & Shipping
  • Pharmacy Disclosure
  • Prescribing Policy
  • Patient Rights & Nondiscrimination
  • Texas Medical Board Complaint Notice
  • SMS Terms
  • Cookies
  • California Privacy
  • Accessibility
Support
  • support@upliftrx.co
  • Member sign in

Medical emergency? Call 911. In crisis? Call or text 988 (Suicide & Crisis Lifeline). UpLiftRX is not for emergencies.

Prescription products require an online consultation with an independent, licensed clinician, who decides whether treatment is appropriate. Available to adults 18+ in states where our clinicians are licensed.

Compounded medications are prepared by state-licensed pharmacies for an individual patient and are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

Latitude Investments Management Ltd. Liability Co. d/b/a UpLiftRX provides a technology platform and is not a pharmacy or a medical provider. Medical services are provided by independent, licensed clinicians of a professional medical group (being finalized). Prescriptions are dispensed by independent, state-licensed pharmacies. Latitude Investments Management Ltd. Liability Co., a Wyoming limited liability company (filing no. 2024-001499647), 5709 Gardendale Dr, STE D, Houston, TX 77092.

Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® and Cialis® are registered trademarks of Eli Lilly and Company. Contrave® is a registered trademark of Currax Pharmaceuticals LLC. Viagra® is a registered trademark of Viatris Specialty LLC. All trademarks are the property of their respective owners. UpLiftRX is not affiliated with or endorsed by any drug manufacturer, and generic medications are not the brand-name products.

© 2026 Latitude Investments Management Ltd. Liability Co. d/b/a UpLiftRX.
  1. Home/
  2. Medications/
  3. Appetite Suppressant/
  4. Contrave® (naltrexone/bupropion ER)
Contrave® (naltrexone/bupropion ER) oral, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant

Contrave® (naltrexone/bupropion ER) Extended-release tablet

Extended-release tablet

FDA-approved oral tablet for chronic weight management that acts on appetite and cravings — a non-injectable option.

$129/ month· clinician care · medication billed by the pharmacy via insurance or manufacturer self-pay
Specification
Just this one: start consultation

Add several treatments and check out once. $0 today; each is charged only if prescribed.

Rx only · adults 18+. Requires an online consultation with an independent, licensed clinician, who decides whether treatment is appropriate. FDA-approved brand-name product; dispensed in manufacturer packaging by a licensed pharmacy.

Safety: Antidepressants such as bupropion increased the risk of suicidal thoughts and behaviors in children, adolescents, and young adults in short-term studies. Important safety information

Know before you start

How Contrave® (naltrexone/bupropion ER) treatment works

How it works

GLP-1 (and dual/triple agonist) medications mimic gut hormones that regulate appetite and blood sugar. They slow stomach emptying and act on appetite centers in the brain, helping you feel full sooner and stay full longer — so sustainable calorie reduction stops being a willpower fight.

What to expect

  • Weeks 1–4: dose titration begins low to minimize nausea; appetite typically quiets noticeably.
  • Months 2–3: dose adjusts based on response and tolerance at your check-ins.
  • Ongoing: monthly shipments, message your care team anytime, labs as clinically indicated.

Common side effects

  • Nausea (most common, usually improves after the first weeks)
  • Constipation or diarrhea
  • Fatigue or headache during titration
  • Injection-site irritation

Safety & who it's not for

Not for patients with a personal/family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, or who are pregnant, breastfeeding, or trying to conceive. Your clinician screens for these and more during intake.

Contrave® (naltrexone/bupropion ER) FAQ

What is Contrave® (naltrexone/bupropion ER)?

FDA-approved oral tablet for chronic weight management that acts on appetite and cravings — a non-injectable option.

What does the research say about Naltrexone?

PubMed indexes 8,940 publications that mention Naltrexone, including 1,217 randomized trials, systematic reviews, or meta-analyses. ClinicalTrials.gov lists 537 registered studies. The sources are linked on this page.

Do I need to diet and exercise too?

These medications work best alongside basic nutrition and activity habits. Your clinician will set realistic expectations — most members find the medication makes those habits dramatically easier to keep.

Is compounded medication the same as the brand?

Compounded drugs are not FDA-approved and are not generic or automatically equivalent to an approved product. When compounding is clinically appropriate and legally available, the exact ingredient form, concentration, route, source, and dispensing facility must be independently verified.

What happens if I stop?

Appetite typically returns toward baseline. Many members taper with their clinician's guidance and keep results with maintenance habits; others stay on a maintenance dose.

Important safety information

Boxed warning: Suicidal thoughts and behaviors

Antidepressants such as bupropion increased the risk of suicidal thoughts and behaviors in children, adolescents, and young adults in short-term studies. Watch for new or worsening depression, unusual changes in mood or behavior, or thoughts of suicide, and contact your clinician right away. Not for use with seizure disorders, eating disorders (bulimia/anorexia), uncontrolled high blood pressure, chronic opioid use, or within 14 days of an MAOI.

Tell your clinician about all medications and supplements you take. Seek emergency care (call 911) for severe reactions. Report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Contrave® is a registered trademark of its owner. UpLiftRX is not affiliated with or endorsed by the manufacturer. Read the full Prescribing Information and Medication Guide from the manufacturer.

Similar products

Similar to Contrave® (naltrexone/bupropion ER)

See all in Appetite Suppressant →
Naltrexone HCl + Bupropion HCl oral, compounded prescription medication, UpLiftRX packagingCompounded · Not FDA-approved
Wellness
Naltrexone HCl + Bupropion HCl
8 mg/90 mg ER
Naltrexone + Yohimbine + Caffeine + DHEA + Cyanocobalamin + Methionine + Inositol + Chromium oral, compounded prescription medication, UpLiftRX packagingCompounded · Not FDA-approved
Wellness
Naltrexone + Yohimbine + Caffeine + DHEA + Cyanocobalamin + Methionine + Inositol + Chromium
8 mg/2.5 mg/25 mg/10 mg/0.5 mg/25 mg/25 mg/100 mcg
Wegovy® (semaglutide) injectable, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant
Wegovy® (semaglutide)
5 options
Zepbound® (tirzepatide) injectable, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant
Zepbound® (tirzepatide)
6 options
Saxenda® (liraglutide) injectable, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant
Saxenda® (liraglutide)
18mg/3mL (0.6–3mg daily)
Orforglipron + Pyridoxine (B6) oral, compounded prescription medication, UpLiftRX packagingCompounded · Not FDA-approved
Appetite Suppressant
Orforglipron + Pyridoxine (B6)
6 options
$129/mo
On this pageOverviewStrengths & pricesHow it's takenStorage & shippingResearch & sourcesFAQReviewsSafety
At a glance

What is Contrave® (naltrexone/bupropion ER) Extended-release tablet?

Contrave® (naltrexone/bupropion ER) is an FDA-approved brand-name prescription medication, dispensed by a licensed pharmacy in the manufacturer's packaging.

Form
Extended-release tablet
Active ingredients
Naltrexone, Bupropion
Options
1 strength and size option
Price
Clinician care from the program price; medication billed by the pharmacy
Prescription
Required. A licensed clinician decides whether it is appropriate.
FDA status
FDA-approved brand-name product, dispensed in the manufacturer's packaging
Dispensed by
A licensed pharmacy
Availability
In stock at one or more pharmacies

Product details from our pharmacy network's catalog, updated October 22, 2026.

Strengths & prices

Contrave® (naltrexone/bupropion ER) Extended-release tablet strengths and prices

1 option. Prices are per month and include the online visit, the medication, and shipping; you are charged only if a clinician prescribes it.
StrengthSizePriceAvailability
8mg/90mg120 tablets (30 days at target dose)—In stock
Clinical research & sources

Research on the ingredients in Contrave® (naltrexone/bupropion ER) Extended-release tablet

Published research and public drug references for each active ingredient, from the U.S. National Library of Medicine (PubMed, MedlinePlus, DailyMed, RxNorm, PubChem), ClinicalTrials.gov, and FDA. Individual results vary.

Naltrexone

FDA status: FDA has approved products that contain naltrexone, including Contrave Extended-Release, Vivitrol.

PubMed: 8,940 publications mention Naltrexone, 1,217 of them trials or reviews. Search PubMed

  1. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. McPheeters M et al. JAMA, 2023. Meta-Analysis, Systematic Review. PMID 37934220 · DOI
  2. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. McGowan B et al. Nature medicine, 2025. Systematic Review, Network Meta-Analysis. PMID 41039116 · DOI
  3. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review. Kim PS et al. Current pain and headache reports, 2020. Systematic Review. PMID 32845365 · DOI
  4. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. Bahji A et al. Journal of addiction medicine, 2022. Systematic Review, Network Meta-Analysis. PMID 35653782 · DOI
  5. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis. Ray LA et al. JAMA network open, 2020. Meta-Analysis, Systematic Review. PMID 32558914 · DOI

ClinicalTrials.gov: 537 registered studies. See all studies

  • NCT05037032 Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude (Phase 4), completed
  • NCT05228418 Bridging ED to Outpatient AUD Therapy With Naltrexone (Phase 4), unknown

MedlinePlus drug information ↗FDA label (DailyMed) ↗RxNorm 7243 ↗PubChem CID 5360515 ↗Wikipedia ↗

Bupropion

FDA status: FDA has approved products that contain bupropion, including Auvelity, Wellbutrin Xl.

PubMed: 5,758 publications mention Bupropion, 1,006 of them trials or reviews. Search PubMed

  1. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Cortese S et al. The lancet. Psychiatry, 2018. Systematic Review, Network Meta-Analysis. PMID 30097390 · DOI
  2. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. Nong K et al. BMJ (Clinical research ed.), 2026. Systematic Review, Network Meta-Analysis. PMID 42419792 · DOI
  3. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Kishi T et al. Molecular psychiatry, 2023. Systematic Review, Network Meta-Analysis. PMID 36253442 · DOI
  4. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. McGowan B et al. Nature medicine, 2025. Systematic Review, Network Meta-Analysis.

Sources checked October 22, 2026. Listing a study is not a claim that this product is safe or effective for you; a licensed clinician makes that decision.

Patient reviews

Reviews come only from patients who received Contrave® (naltrexone/bupropion ER) Extended-release tablet through UpLiftRX. Each is checked for privacy and safety before it's published; we never remove a review for being negative. Individual experiences vary, and reviews aren't medical advice.

No reviews yet. Patients who receive Contrave® (naltrexone/bupropion ER) Extended-release tablet through UpLiftRX can leave a review after delivery.

For patients who received Contrave® (naltrexone/bupropion ER) Extended-release tablet.
PMID 41039116
· DOI
  • Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). Iosifescu DV et al. The Journal of clinical psychiatry, 2022. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 35649167 · DOI
  • ClinicalTrials.gov: 509 registered studies. See all studies

    • NCT01456936 Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders (Phase 4), completed

    MedlinePlus drug information ↗FDA label (DailyMed) ↗RxNorm 42347 ↗PubChem CID 444 ↗Wikipedia ↗